The cellular pharmacokinetics of HIV protease inhibitors: Current knowledge and future perspectives

Current Drug Metabolism

Volumn 13, Issue 8, 2012, Pages 1174-1183

  Zha, Weibin ^a   Zha, Beth S ^b   Zhou, Fang ^a   Zhou, Huiping ^b,c   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cellular pharmacokinetics; HIV protease inhibitor; Metabolic enzymes; Pharmacokinetics pharmcodynamics; Toxicity; Transporters

Indexed keywords

ABC TRANSPORTER; AMPRENAVIR; ATAZANAVIR; CYTOCHROME P450; DARUNAVIR; ELACRIDAR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VERLUKAST;

BRAIN CELL; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; DRUG EFFICACY; DRUG RESEARCH; DYSLIPIDEMIA; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INTESTINE CELL; LIPID MEMBRANE; LIPODYSTROPHY; LIPOPHILICITY; LIVER CELL; LIVER TOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL CHEMISTRY; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; CELLS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 84868027243     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802850119     Document Type: Review

References (109)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic: 2010. WHO, 2010.
2. Flexner, C. HIV-protease inhibitors. N. Engl. J. Med., 1998, 338(18), 1281-1292.
3. Este, J.A.; Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res., 2010, 85(1), 25-33.
4. Ford, J.; Khoo, S.H.; Back, D.J. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother., 2004, 54(6), 982-990.
5. Kim, R.B. Drug transporters in HIV Therapy. Top HIV Med., 2003, 11(4), 136-139.
6. Pal, D.; Mitra, A.K. MDR- and CYP3A4-mediated drug-drug interactions. J. Neuroimmune. Pharmacol., 2006, 1(3), 323-339.
7. Barbaro, G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am. J. Ther., 2006, 13(3), 248-260.
8. Anuurad, E.; Bremer, A.; Berglund, L. HIV protease inhibitors and obesity. Curr. Opin. Endocrinol. Diabetes Obes., 2010, 17(5), 478-485.
9. Nunez, M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology, 2010, 52(3), 1143-1155.
10. Justesen, U.S. Protease inhibitor plasma concentrations in HIV antiretroviral therapy. Dan. Med. Bull., 2008, 55(4), 165-185.
11. Roustit, M.; Jlaiel, M.; Leclercq, P.; Stanke-Labesque, F. Pharma-cokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br. J. Clin. Pharmacol., 2008, 66(2), 179-195.
12. Pawinski, T.; Pulik, P.; Gralak, B.; Horban, A. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. Acta. Pol. Pharm., 2008, 65(1), 93-100.
13. Ribera, E.; Lopez-Cortes, L.F.; Soriano, V.; Casado, J.L.; Mallolas, J. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation? Enferm. Infecc. Microbiol. Clin., 2005, 23(Suppl 2), 41-67.
14. Justesen, U.S. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy. Basic. Clin. Pharmacol. Toxicol., 2006, 98(1), 20-31.
15. Lotsch, J.; Harder, S.; Sturmer, M.; Doerr, H.W.; Geisslinger, G.; Staszewski, S.; von Hentig, N. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 2007, 51(9), 3264-3272.
16. Josephson, F.; Andersson, M.C.; Flamholc, L.; Gisslen, M.; Hagberg, L.; Ormaasen, V.; Sonnerborg, A.; Vesterbacka, J.; Bottiger, Y. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Eur. J. Clin. Pharmacol., 2010, 66(4), 349-357.
17. Autar, R.S.; Boyd, M.A.; Wit, F.W.; Ruxrungthams, K.; Sankote, J.; Lange, J.; Cooper, D.A.; Phanuphak, P.; Burger, D.M.; Reiss, P. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antivir. Ther., 2007, 12(8), 1265-1271.
18. Ter Heine, R.; Mulder, J.W.; van Gorp, E.C.; Wagenaar, J.F.; Beijnen, J.H.; Huitema, A.D. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br. J. Clin. Pharmacol., 2010, 69(5), 475-483.
19. Ford, J.; Boffito, M.; Wildfire, A.; Hill, A.; Back, D.; Khoo, S.; Nelson, M.; Moyle, G.; Gazzard, B.; Pozniak, A. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 2004, 48(7), 2388-2393.
20. Hennessy, M.; Clarke, S.; Spiers, J.P.; Kelleher, D.; Mulcahy, F.; Hoggard, P.; Back, D.; Barry, M. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir. Ther., 2004, 9(1), 115-122.
21. Bazzoli, C.; Jullien, V.; Le Tiec, C.; Rey, E.; Mentre, F.; Taburet, A.M. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin. Pharmacokinet., 2010, 49(1), 17-45.
22. Owen, A.; Khoo, S.H. Intracellular pharmacokinetics of antiretroviral agents. J. HIV Ther., 2004, 9(4), 97-101.
23. Griffin, L.; Annaert, P.; Brouwer, K.L. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J. Pharm. Sci., 2011, 100(9), 3636-3654.
24. Ford, J.; Boffito, M.; Maitland, D.; Hill, A.; Back, D.; Khoo, S.; Nelson, M.; Moyle, G.; Gazzard, B.; Pozniak, A. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J. Antimicrob. Chemother., 2006, 58(5), 1009-1016.
25. Meaden, E.R.; Hoggard, P.G.; Newton, P.; Tjia, J.F.; Aldam, D.; Cornforth, D.; Lloyd, J.; Williams, I.; Back, D.J.; Khoo, S.H. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J. Antimicrob. Chemother., 2002, 50(4), 583-588.
26. Janneh, O.; Bray, P.G.; Jones, E.; Wyen, C.; Chiba, P.; Back, D.J.; Khoo, S.H. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother., 2010, 65(5), 906-916.
27. Jones, K.; Hoggard, P.G.; Sales, S.D.; Khoo, S.; Davey, R.; Back, D.J. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. Aids, 2001, 15(6), 675-681.
28. Hennessy, M.; Clarke, S.; Spiers, J.P.; Mulcahy, F.; Kelleher, D.; Meadon, E.; Maher, B.; Bergin, C.; Khoo, S.; Tjia, J.; Hoggard, P.; Back, D.; Barry, M. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. Antivir. Ther., 2003, 8(3), 191-198.
29. Chaillou, S.; Durant, J.; Garraffo, R.; Georgenthum, E.; Roptin, C.; Clevenbergh, P.; Dunais, B.; Mondain, V.; Roger, P.M.; Dellamonica, P. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin. Trials, 2002, 3(6), 493-501.
30. Elens, L.; Yombi, J.C.; Lison, D.; Wallemacq, P.; Vandercam, B.; Haufroid, V. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics, 2009, 10(10), 1589-1597.
31. Janneh, O.; Jones, E.; Chandler, B.; Owen, A.; Khoo, S.H. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother., 2007, 60(5), 987-993.
32. Fayet Mello, A.; Buclin, T.; Franc, C.; Colombo, S.; Cruchon, S.; Guignard, N.; Biollaz, J.; Telenti, A.; Decosterd, L.A.; Cavassini, M. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J. Antimicrob. Chemother., 2011, 66(7), 1573-1581.
33. Kwan, W.S.; Janneh, O.; Hartkoorn, R.; Chandler, B.; Khoo, S.; Back, D.; Owen, A. Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br. J. Clin. Pharmacol., 2009, 68(3), 375-380.
34. Storch, C.H.; Theile D.; Lindenmaier H.; Haefeli W.E.; Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol., 2007, 73(10), 1573-1581.
35. Gupta, A.; Mugundu, G.M.; Desai, P.B.; Thummel, K.E.; Unadkat, J.D. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab. Dispos., 2008, 36(6), 1172-1180.
36. Huisman, M.T.; Smit, J.W.; Crommentuyn, K.M.; Zelcer, N.; Wiltshire, H.R.; Beijnen, J.H.; Schinkel, A.H. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids, 2002, 16(17), 2295-2301.
37. Agarwal, S.; Pal, D.; Mitra, A.K. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int. J. Pharm., 2007, 339(1-2), 139-147.
38. Bierman, W.F.; Scheffer, G.L.; Schoonderwoerd, A.; Jansen, G.; van Agtmael, M.A.; Danner, S.A.; Scheper, R.J. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC trans-porter-overexpressing cell lines. J. Antimicrob. Chemother., 2010, 65(8), 1672-1680.
39. Ye, Z.W.; Camus, S.; Augustijns, P.; Annaert, P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm. Drug Dispos., 2010, 31(2-3), 178-188.
40. Konig, S.K.; Herzog, M.; Theile, D.; Zembruski, N.; Haefeli, W.E.; Weiss, J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother., 2010, 65(11), 2319-2328.
41. Gupta, A.; Zhang, Y.; Unadkat, J.D.; Mao, Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther., 2004, 310(1), 334-341.
42. Weiss, J.; Rose, J.; Storch, C.H.; Ketabi-Kiyanvash, N.; Sauer, A.; Haefeli, W.E.; Efferth, T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother., 2007, 59(2), 238-245.
43. Janneh, O.; Hartkoorn, R.C.; Jones, E.; Owen, A.; Ward, S.A.; Davey, R.; Back, D.J.; Khoo, S.H. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br. J. Pharmacol., 2008, 155(6), 875-883.
44. Su, Y.; Zhang, X.; Sinko, P.J. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm., 2004, 1(1), 49-56.
45. Annaert, P.; Ye, Z.W.; Stieger, B.; Augustijns, P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica, 2010, 40(3), 163-176.
46. Ye, Z.W.; Van Pelt, J.; Camus, S.; Snoeys, J.; Augustijns, P.; Annaert, P. Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes. J. Pharm. Sci., 2010, 99(6), 2886-2898.
47. Zhang, L.; Gorset, W.; Washington, C.B.; Blaschke, T.F.; Kroetz, D.L.; Giacomini K.M. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos., 2000, 28(3), 329-334.
48. Dixit, V.; Hariparsad, N.; Li, F.; Desai, P.; Thummel, K.E.; Unadkat, J.D. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos., 2007, 35(10), 1853-1859.
49. Granfors, M.T.; Wang, J.S.; Kajosaari, L.I.; Laitila, J.; Neuvonen, P.J.; Backman, J.T. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic. Clin. Pharmacol. Toxicol., 2006, 98(1), 79-85.
50. Eagling, V.A.; Back, D.J.; Barry, M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol., 1997, 44 (2),190-194.
51. Kis, O.; Zastre, J.A.; Ramaswamy, M.; Bendayan, R. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J. Pharmacol. Exp. Ther., 2010, 334(3), 1009-1022.
52. Jung, N.; Lehmann, C.; Rubbert, A.; Knispel, M.; Hartmann, P.; van Lunzen, J.; Stellbrink, H.J.; Faetkenheuer, G.; Taubert, D. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos., 2008, 36(8), 1616-1623.
53. Fitzsimmons, M.E.; Collins, J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos., 1997, 25(2), 256-266.
54. Chiba, M.; Hensleigh, M.; Nishime, J.A.; Balani, S.K.; Lin, J.H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos., 1996, 24(3), 307-314.
55. Kumar, G.N.; Rodrigues, A.D.; Buko, A.M.; Denissen, J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277(1), 423-431.
56. Hirt, D.; Mentre, F.; Tran, A.; Rey, E.; Auleley, S.; Salmon, D.; Duval, X.; Treluyer, J.M. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br. J. Clin. Pharmacol., 2008, 65(4), 548-557.
57. Treluyer, J.M.; Bowers, G.; Cazali, N.; Sonnier, M.; Rey, E.; Pons, G.; Cresteil, T. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab. Dispos., 2003, 31(3), 275-281.
58. Wempe, M.F.; Anderson, P.L. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab. Dispos., 2011, 39(3), 522-527.
59. Hyland, R.; Dickins, M.; Collins, C.; Jones, H.; Jones, B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br. J. Clin. Pharmacol., 2008, 66(4), 498-507.
60. van Waterschoot, R.A.; ter Heine, R.; Wagenaar, E.; van der Kruijssen, C.M.; Rooswinkel, R.W.; Huitema, A.D.; Beijnen, J.H.; Schinkel, A.H. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br. J. Pharmacol., 2010, 160(5), 1224-1233.
61. McKeage, K.; Perry, C.M.; Keam, S.J. Darunavir: a review of its use in the management of HIV infection in adults. Drugs, 2009, 69(4), 477-503.
62. Li, F.; Wang, L.; Guo, G.L.; Ma, X. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab. Dispos., 2010, 38(5), 871-878.
63. de Maat, M.M.; Ekhart, G.C.; Huitema, A.D.; Koks, C.H.; Mulder, J.W.; Beijnen, J.H. Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet., 2003, 42(3), 223-282.
64. Gagnon, R.F.; Alli, A.I.; Edwardes, M.D.; Watters, A.K.; Tsoukas, C.M. Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals. Clin. Nephrol., 2006, 65(1), 13-21.
65. Diker, B.; Janneh, O.; van Heeswijk, R.P.; Copeland, K.F. Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells. Drug Metab. Lett., 2010, 4(4), 241-245.
66. Jones, K.; Bray, P.G.; Khoo, S.H.; Davey, R.A.; Meaden, E.R.; Ward, S.A.; Back, D.J. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? Aids, 2001, 15(11), 1353-1358.
67. Malorni, W.; Lucia, M.B.; Rainaldi, G.; Cauda, R.; Cianfriglia, M.; Donelli, G.; Ortona, L. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica, 1998, 83(1), 13-20.
68. Prechtl, S.; Roellinghoff, M.; Scheper, R.; Cole, S.P.; Deeley, R.G.; Lohoff, M. The multidrug resistance protein 1: a functionally important activation marker for murine Th1 cells. J. Immunol., 2000, 164(2), 754-761.
69. Oselin, K.; Mrozikiewicz, P.M.; Pahkla, R.; Roots, I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur. J. Haematol., 2003, 71(2), 119-123.
70. Wang, X.; Baba, M. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir. Chem. Chemother., 2005, 16(4), 213-216.
71. Wang, X.; Furukawa, T.; Nitanda, T.; Okamoto, M.; Sugimoto, Y.; Akiyama, S.; Baba, M. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol., 2003, 63(1), 65-72.
72. Janneh, O.; Chandler, B.; Hartkoorn, R.; Kwan, W.S.; Jenkinson, C.; Evans, S.; Back, D.J.; Owen, A.; Khoo, S.H. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother., 2009, 64(5), 1002-1007.
73. Janneh, O.; Owen, A.; Chandler, B.; Hartkoorn, R.C.; Hart, C.A.; Bray, P.G.; Ward, S.A.; Back, D.J.; Khoo, S.H. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. Aids, 2005, 19(18), 2097-2102.
74. Janneh, O.; Anwar, T.; Jungbauer, C.; Kopp, S.; Khoo, S.H.; Back, D.J.; Chiba, P. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir. Ther., 2009, 14(7), 965-974.
75. Khaliq, Y.; Gallicano, K.; Venance, S.; Kravcik, S.; Cameron, D.W. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther., 2000, 68(6), 637-646.
76. Polis, M.A.; Suzman, D.L.; Yoder, C.P.; Shen, J.M.; Mican, J.M.; Dewar, R.L.; Metcalf, J.A.; Falloon, J.; Davey, R.T. Jr.; Kovacs, J.A.; Feinberg, M.B.; Masur, H.; Piscitelli, S.C. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. Aids, 2003, 17(8), 1167-1172.
77. Park, S.; Sinko, P.J. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther., 2005, 312(3), 1249-1256.
78. van der Sandt, I.C.; Vos, C.M.; Nabulsi, L.; Blom-Roosemalen, M.C.; Voorwinden, H.H.; de Boer, A.G.; Breimer, D.D. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood - brain barrier. Aids, 2001, 15(4), 483-491.
79. Perloff, M.D.; von Moltke, L.L.; Fahey, J.M.; Greenblatt, D.J. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J. Pharm. Pharmacol., 2007, 59(7), 947-953.
80. Gimenez, F.; Fernandez, C.; Mabondzo, A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J. Acquir. Immune. Defic. Syndr., 2004, 36(2), 649-658.
81. Haas, D.W.; Johnson, B.; Nicotera, J.; Bailey, V.L.; Harris, V.L.; Bowles, F.B.; Raffanti, S.; Schranz, J.; Finn, T.S.; Saah, A.J.; Stone, J. Effects of ritonavir on indinavir pharmacokinetics in cere-brospinal fluid and plasma. Antimicrob. Agents Chemother., 2003, 47(7), 2131-2137.
82. Strazza, M.; Pirrone, V.; Wigdahl, B.; Nonnemacher, M.R. Breaking down the barrier: The effects of HIV-1 on the blood-brain barrier. Brain Res., 2011, 1399, 96-115.
83. Hill, A.; van der Lugt, J.; Sawyer, W.; Boffito, M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. Aids, 2009, 23(17), 2237-2245.
84. Perloff, M.D.; von Moltke, L.L.; Greenblatt, D.J. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica, 2004, 34(2), 133-150.
85. Bow, D.A.; Perry, J.L.; Miller, D.S.; Pritchard, J.B.; Brouwer, K.L. Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab. Dispos., 2008, 36(1), 198-202.
86. Kojima, H.; Nies, A.T.; Konig, J.; Hagmann, W.; Spring, H.; Uemura, M.; Fukui, H.; Keppler, D. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J. Hepatol., 2003, 39(5), 693-702.
87. Zhou, H.; Gurley, E.C.; Jarujaron, S.; Ding, H.; Fang, Y.; Xu, Z.; Pandak, W.M. Jr.; Hylemon, P.B. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 291(6), G1071-1080.
88. Grossman, S.J.; Reinford, N.; Anderson, C.; Eydelloth, R.S.; Alberts, D.W.; Smith, P.F.; Patrick, D.H. Hepatotoxicity of an HIV protease inhibitor in dogs and rats. Toxicol. Appl. Pharmacol., 1997, 146(1), 40-52.
89. Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos., 1998, 26(6), 552-561.
90. Berginc, K.; Trdan, T.; Trontelj, J.; Kristl, A. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharm. Drug Dispos., 2010, 31(8-9), 495-505.
91. Agarwal, S.; Boddu, S.H.; Jain, R.; Samanta, S.; Pal, D.; Mitra, A.K. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int. J. Pharm., 2008, 359(1-2), 7-14.
92. Jain, R.; Agarwal, S.; Mandava, N.K.; Sheng, Y.; Mitra, A.K. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux. Int. J. Pharm., 2008, 362(1-2), 44-51.
93. Jain, R.; Duvvuri, S.; Kansara, V.; Mandava, N.K.; Mitra, A.K. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int. J. Pharm., 2007, 336(2), 233-240.
94. Wu, X.; Sun, L.; Zha, W.; Studer, E.; Gurley, E.; Chen, L.; Wang, X.; Hylemon, P.B.; Pandak, W.M. Jr.; Sanyal, A.J.; Zhang, L.; Wang, G.; Chen, J.; Wang, J.Y.; Zhou, H. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology, 2010, 138(1), 197-209.
95. Braga Neto, M.B.; Aguiar, C.V.; Maciel, J.G.; Oliveira, B.M.; Sevilleja, J.E.; Oria, R.B.; Brito, G.A.; Warren, C.A.; Guerrant, R.L.; Lima, A.A. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol., 2010, 10, 90.
96. Vernochet, C.; Azoulay, S.; Duval, D.; Guedj, R.; Cottrez, F.; Vidal, H.; Ailhaud, G.; Dani, C. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J. Biol. Chem., 2005, 280(3), 2238-2243.
97. Vernochet, C.; Azoulay, S.; Duval, D.; Guedj, R.; Ailhaud, G.; Dani, C. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. Aids, 2003, 17(15), 2177-2180.
98. Janneh, O.; Hoggard, P.G.; Tjia, J.F.; Jones, S.P.; Khoo, S.H.; Maher, B.; Back, D.J.; Pirmohamed, M. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir. Ther., 2003, 8(5), 417-426.
99. Janneh, O.; Owen, A.; Bray, P.G.; Back, D.J.; Pirmohamed, M. The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. Br. J. Pharmacol., 2010, 159(2), 484-493.
100. Jain, R.; Agarwal, S.; Majumdar, S.; Zhu, X.; Pal, D.; Mitra, A.K. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm., 2005, 303(1-2), 8-19.
101. Mahajan, S.D.; Roy, I.; Xu, G.; Yong, K.T.; Ding, H.; Aalinkeel, R.; Reynolds, J.; Sykes, D.; Nair, B.B.; Lin, E.Y.; Prasad, P.N.; Schwartz, S.A. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr. HIV Res., 2010, 8(5), 396-404.
102. Vyas, T.K.; Shahiwala, A.; Amiji, M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm., 2008, 347(1-2), 93-101.
103. Shah, L.K.; Amiji, M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res., 2006, 23(11), 2638-2645.
104. Kinman. L.; Bui. T.; Larsen. K.; Tsai. C.C.; Anderson. D.; Morton. W.R.; Hu, S.L.; Ho, R.J. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J. Acquir. Immune Defic. Syndr., 2006, 42(2), 155-161.
105. Aji Alex, M.R.; Chacko, A.J.; Jose, S.; Souto, E.B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci., 2011, 42(1-2), 11-18.
106. Van Bambeke, F.; Carryn, S.; Seral, C.; Chanteux, H.; Tyteca, D.; Mingeot-Leclercq, M.P.; Tulkens, P.M. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother., 2004, 48(8), 2853-2860.
107. Hoffmann, J.; Vitale, I.; Buchmann, B.; Galluzzi, L.; Schwede, W.; Senovilla, L.; Skuballa, W.; Vivet, S.; Lichtner, R.B.; Vicencio, J.M.; Panaretakis, T.; Siemeister, G.; Lage, H.; Nanty, L.; Hammer, S.; Mittelstaedt, K.; Winsel, S.; Eschenbrenner, J.; Castedo, M.; Demarche, C.; Klar, U.; Kroemer, G. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res., 2008, 68(13), 5301-5308.
108. Zhou, F.; Zhang, J.; Li, P.; Niu, F.; Wu, X.; Wang, G.; Roberts, M.S. Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metab. Rev., 2011, 43(3), 335-345.
109. Zhang, J.; Zhou, F.; Wu, X.; Zhang, X.; Chen, Y.; Zha, B.S.; Niu, F.; Lu, M.; Hao, G.; Sun, Y.; Sun, J.; Peng, Y.; Wang, G. Cellular Pharmacokinetic Mechanisms of Adriamycin Resistance and Its Modulation by 20(S)-Ginsenoside Rh2 in MCF-7/Adr Cells. Br. J. Pharmacol., 2011, 165(1), 120-134.